Carasent ASA (OSL: CARA)
Norway
· Delayed Price · Currency is NOK
20.00
0.00 (0.00%)
Nov 21, 2024, 4:25 PM CET
Carasent ASA Revenue
Carasent ASA had revenue of 66.31M NOK in the quarter ending September 30, 2024, with 19.43% growth. This brings the company's revenue in the last twelve months to 264.80M, up 12.57% year-over-year. In the year 2023, Carasent ASA had annual revenue of 243.98M with 24.95% growth.
Revenue (ttm)
264.80M
Revenue Growth
+12.57%
P/S Ratio
5.49
Revenue / Employee
1.57M
Employees
165
Market Cap
1.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 243.98M | 48.72M | 24.95% |
Dec 31, 2022 | 195.26M | 58.14M | 42.40% |
Dec 31, 2021 | 137.13M | 66.55M | 94.29% |
Dec 31, 2020 | 70.58M | 22.65M | 47.26% |
Dec 31, 2019 | 47.93M | 23.96M | 99.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nordhealth AS | 513.12M |
Medistim ASA | 541.82M |
Photocure ASA | 526.25M |
Nykode Therapeutics AS | 69.44M |
ArcticZymes Technologies ASA | 110.76M |
Gentian Diagnostics ASA | 154.12M |
Hofseth BioCare ASA | 248.08M |
Navamedic ASA | 525.55M |